Inductos (dibotermin alfa)
- Region
- 🇪🇺 EU
- Active substance
- dibotermin alfa
- Company
- Medtronic BioPharma B.V.
- Status
- Authorised
- Therapeutic area
- Tibial Fractures; Fracture Fixation, Internal; Spinal Fusion
- EU approval
- Mon 09 Sep 2002
- Application
- EMEA/H/C/000408
- ATC
- M05BC01
- Official record
- www.ema.europa.eu
Indication
Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition. Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.
Regulatory milestones
No milestones recorded in the last year.
Follow Inductos
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.